Delivery Order SPE2DB22D2206-SPE2DB24FFG07
- Not listed
- This federal contract award, valued at $18,411.17, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract is a Firm Fixed Price Delivery Order with a completion date of July 17, 2024. It is not designated as a set-aside contract. AmerisourceBergen holds a larger...
- This federal contract award, valued at $4,194.00, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a medication used to treat dry eye disease. This is a firm fixed-price delivery order contract with a period of performance through November 15, 2024. The contract does not have a set-aside designation, indicating it was open...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,948.36 firm-fixed-price delivery order contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of October 23, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,528.08 Firm Fixed Price Delivery Order is for the supply of RESTASIS 0.05% Eye Emulsion, a specialty ophthalmic medication. The award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,958.72 Delivery Order contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support...
- This federal contract award, valued at $11,648.39, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, with a completion date of October 21, 2024. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $19,847.38 firm fixed-price delivery order is for the provision of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of January 31, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,083.53 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a medication used to treat dry eye disease. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which enables the government to...
- This federal contract award, valued at $2,745.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a Firm Fixed Price Delivery Order for the supply of RESTASIS 0.05% Eye Emulsion 30s, a prescription eye medication. The contract has an ultimate completion date of May 28, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which serves...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,117.80 firm fixed-price delivery order is for the provision of RESTASIS 0.05% eye emulsion, a prescription ophthalmic medication. The contract has an ultimate completion date of March 17, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB24FFG07Delivery Order
This federal contract award, valued at $13,438.81, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription medication used to treat chronic dry eye. The award is a Firm Fixed Price Delivery Order contract, with a period of performance running through January 25, 2024. It is not designated as a set-aside contract. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.4k | 1/24/24 |